MétaCan
Menu
Back to cohort

Stereotactic Body Radiotherapy Without Systemic Therapy for Oligometastatic Cancer

2025· article· en· W7117501212 on OpenAlexaff
Jonas Willmann, Camilla von Wachter, R. Zehnder, Edward Christopher Dee, Hanbo Chen, Lizza E. L. Hendriks, Jordi Remon, Sarah Baker, Michael Mayinger, N. Andratschke, Narek Shaverdian, D. Gomez, U. Ricardi, Robert Olson, Arjun Sahgal, Dirk De Ruysscher, Puneeth Iyengar, Matthias Gückenberger

Bibliographic record

VenueJAMA Network Open · 2025
Typearticle
Languageen
FieldMedicine
TopicManagement of metastatic bone disease
Canadian institutionsUniversity of British ColumbiaBC Cancer AgencySunnybrook Health Science Centre
FundersNational Cancer InstituteServierSeagenViewRayIncyteNovocureElektaMedtronicBeiGeneOlympusVarian Medical SystemsRegeneron PharmaceuticalsNovartisAmgenPfizerAstraZenecaEli Lilly and Company
KeywordsSystemic therapyProstate cancerRadiation therapyAdverse effectCancerRadiosurgeryCyberknifeSABR volatility model

Abstract

fetched live from OpenAlex

Importance: Metastasis-directed stereotactic body radiotherapy (SBRT) may be a viable strategy to defer systemic therapy in patients with oligometastatic cancer due to comorbidities, patient preferences, or concerns about adverse effects. To date, the evidence supporting this approach has not been comprehensively assessed. Objective: To evaluate systemic therapy-free survival (STFS) for different types of oligometastatic cancer after SBRT alone and to quantify adverse events, quality of life, and oncological outcomes. Data Sources: A systematic search of PubMed and EMBASE was conducted on July 10, 2024, to identify potentially eligible studies published after 2009. Forward and backward citation tracking was performed to identify additional relevant studies. Study Selection: Studies eligible for inclusion in the systematic review were retrospective or prospective with at least 10 patients who received metastasis-directed SBRT and no up-front systemic therapy for oligometastatic cancer (≤5 metastases) irrespective of primary tumor histology. Required outcomes being reported were STFS, progression-free survival, or overall survival. The subgroup of studies reporting STFS at 1 or 2 years were included in a meta-analysis of these pooled outcomes. Data Extraction and Synthesis: Two reviewers independently extracted data using predefined forms and followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A random-effects model was used for meta-analysis. Main Outcomes and Measures: The primary outcome of the meta-analysis was the pooled STFS rate at 1 or 2 years. Results: Of 29 unique studies (2074 unique patients) included in the systematic review, 13 (984 patients) contributed data to the meta-analysis. The pooled 1- or 2-year STFS rate was 69.7% (95% CI, 57.4%-80.9%) across cancer types. Renal cell cancer demonstrated the highest STFS rate (87.0%; 95% CI, 76.2%-95.2%), followed by prostate cancer (78.1%; 95% CI, 67.4%-87.3%), with lower rates in other cancer types. Among 20 studies reporting adverse events, rates of adverse effects of grade 3 or higher were absent in 15 of 19 studies (79%) and ranged from 2 of 103 (1.9%) to 3 of 34 patients (8.8%) among those that observed severe adverse events. Conclusions and Relevance: In this systematic review and meta-analysis, metastasis-directed SBRT alone was associated with meaningful STFS, particularly in patients with oligometastatic prostate or renal cell cancer, with low risks of treatment-related adverse events. These findings suggest that SBRT alone might be an acceptable option instead of immediate systemic therapy in selected patients with oligometastatic cancer.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.170
Threshold uncertainty score0.946

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0010.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.031
GPT teacher head0.371
Teacher spread0.339 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations4
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueJAMA Network OpenSame topicManagement of metastatic bone diseaseFrench-language works237,207